2 results
Approved WMOCompleted
To determine the within and between variability of pharmacokinetic (PK) profiles in patients treated with DOACs in daily practice
Approved WMOCompleted
To test the hypothesis that mirikizumab is superior to placebo in inducing clinical remission at Week 12 in patients with moderately to severely active ulcerative colitis (UC)